Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: m6A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling

Fig. 1

The expression and prognostic value of BATF2 in GC. a Flowchart of the screening process of candidate genes. b The FPKM (fragments per kilobase million) of BATF2 in gastric tumor and adjacent normal tissues. c The mRNA levels of BATF2 in gastric tumor and adjacent normal tissues were measured by qRT-PCR. d Representative images of BATF2 protein levels in gastric tumor and adjacent normal tissues. e The T/N ratios of the total results described in d. f The basic protein expression of BATF2 in normal gastric epithelial cells (GES-1) and GC cell lines (HGC-27, MGC-803, AGS, MKN-45 and SNU-216) was detected by western blotting and quantified (**P < 0.01; ***P < 0.001). g The expression of BATF2 in 352 paraffin-embedded specimens from the internal cohort was determined by TMA-based IHC staining. Scale bars = 200 μm. h-i Kaplan-Meier analyses of the correlations between BATF2 expression and overall survival or disease-free survival in the internal cohort (P < 0.05). j The BATF2 IHC scores in the internal cohort are shown as box plots. A negative correlation was detected between the BATF2 IHC scores in GC and the frequency of peritoneal recurrence (***P < 0.001; P-rec: peritoneal recurrence). k BATF2 IHC scores in paired normal and gastric tumor tissues according to disease stage and the presence or absence of peritoneal recurrence (***P < 0.001; P-rec: peritoneal recurrence). l The cumulative incidence of peritoneal recurrence in GC patients with different BATF2 expression levels from the internal cohort (P < 0.05)

Back to article page